Does the media favor AXSM or OGN?

In the previous week, Axsome Therapeutics had 9 more articles in the media than Organon & Co.. MarketBeat recorded 12 mentions for Axsome Therapeutics and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.09 beat Axsome Therapeutics' score of 0.75 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OGN or ELAN?

In the previous week, Elanco Animal Health had 2 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Elanco Animal Health and 3 mentions for Organon & Co.. Elanco Animal Health's average media sentiment score of 1.16 beat Organon & Co.'s score of 1.09 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer OGN or RDY?

Organon & Co. presently has a consensus target price of $11.40, indicating a potential downside of 15.59%. Given Organon & Co.'s stronger consensus rating and higher possible upside, equities analysts plainly believe Organon & Co. is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media favor OGN or RDY?

In the previous week, Dr. Reddy's Laboratories had 2 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Dr. Reddy's Laboratories and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.09 beat Dr. Reddy's Laboratories' score of -0.18 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to OGN or SMMT?

In the previous week, Organon & Co. and Organon & Co. both had 3 articles in the media. Summit Therapeutics' average media sentiment score of 1.67 beat Organon & Co.'s score of 1.09 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to OGN or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Arrowhead Pharmaceuticals and 3 mentions for Organon & Co.. Arrowhead Pharmaceuticals' average media sentiment score of 1.20 beat Organon & Co.'s score of 1.09 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Organon & Co. (OGN) Competitors

$13.50 -0.02 (-0.11%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$13.49 -0.01 (-0.08%)

As of 07/13/2026 07:48 PM Eastern

Compare

OGN vs. AXSM, ELAN, RDY, SMMT, and ARWR

Should you buy Organon & Co. stock or one of its competitors? MarketBeat compares Organon & Co. with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organon & Co. include Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Summit Therapeutics (SMMT), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Organon & Co. compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Organon & Co. has a net margin of 3.99% compared to Axsome Therapeutics' net margin of -26.59%. Organon & Co.'s return on equity of 99.95% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Organon & Co.	3.99%	99.95%	6.22%

Axsome Therapeutics currently has a consensus target price of $259.05, suggesting a potential upside of 13.48%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 15.59%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

In the previous week, Axsome Therapeutics had 9 more articles in the media than Organon & Co.. MarketBeat recorded 12 mentions for Axsome Therapeutics and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.09 beat Axsome Therapeutics' score of 0.75 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.40	-$183.17M	-$3.73	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.52

Summary

Organon & Co. beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Elanco Animal Health?

Organon & Co. (NYSE:OGN) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Organon & Co. currently has a consensus price target of $11.40, indicating a potential downside of 15.59%. Elanco Animal Health has a consensus price target of $28.55, indicating a potential upside of 13.61%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Organon & Co. has a net margin of 3.99% compared to Elanco Animal Health's net margin of -4.95%. Organon & Co.'s return on equity of 99.95% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Elanco Animal Health	-4.95%	7.42%	3.66%

Organon & Co. has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.52
Elanco Animal Health	$4.72B	2.66	-$232M	-$0.50	N/A

In the previous week, Elanco Animal Health had 2 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Elanco Animal Health and 3 mentions for Organon & Co.. Elanco Animal Health's average media sentiment score of 1.16 beat Organon & Co.'s score of 1.09 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Summary

Elanco Animal Health beats Organon & Co. on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Organon & Co. (NYSE:OGN) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Dr. Reddy's Laboratories has lower revenue, but higher earnings than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.52
Dr. Reddy's Laboratories	$3.58B	3.02	$456M	$0.58	22.30

In the previous week, Dr. Reddy's Laboratories had 2 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Dr. Reddy's Laboratories and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.09 beat Dr. Reddy's Laboratories' score of -0.18 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Dr. Reddy's Laboratories pays an annual dividend of $0.07 per share and has a dividend yield of 0.5%. Organon & Co. pays out 8.6% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 12.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Organon & Co. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Organon & Co. has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Organon & Co. presently has a consensus target price of $11.40, indicating a potential downside of 15.59%. Given Organon & Co.'s stronger consensus rating and higher possible upside, equities analysts plainly believe Organon & Co. is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Organon & Co.'s net margin of 3.99%. Organon & Co.'s return on equity of 99.95% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Summary

Organon & Co. beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Summit Therapeutics?

Organon & Co. (NYSE:OGN) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Organon & Co. has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market.

Organon & Co. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.52
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Organon & Co. currently has a consensus price target of $11.40, suggesting a potential downside of 15.59%. Summit Therapeutics has a consensus price target of $26.97, suggesting a potential upside of 76.29%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Organon & Co. has a net margin of 3.99% compared to Summit Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Summit Therapeutics	N/A	-291.24%	-243.07%

In the previous week, Organon & Co. and Organon & Co. both had 3 articles in the media. Summit Therapeutics' average media sentiment score of 1.67 beat Organon & Co.'s score of 1.09 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Organon & Co. beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Organon & Co. compare to Arrowhead Pharmaceuticals?

Organon & Co. (NYSE:OGN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Organon & Co. has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.52
Arrowhead Pharmaceuticals	$829.45M	12.59	-$1.63M	-$2.15	N/A

Organon & Co. has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Organon & Co. has a net margin of 3.99% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Organon & Co.'s return on equity of 99.95% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Organon & Co. currently has a consensus price target of $11.40, suggesting a potential downside of 15.59%. Arrowhead Pharmaceuticals has a consensus price target of $87.27, suggesting a potential upside of 17.76%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Arrowhead Pharmaceuticals and 3 mentions for Organon & Co.. Arrowhead Pharmaceuticals' average media sentiment score of 1.20 beat Organon & Co.'s score of 1.09 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Organon & Co. beats Arrowhead Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGN vs. The Competition

Export

Metric	Organon & Co.	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$3.55B	$9.60B	$7.05B	$23.46B
Dividend Yield	0.59%	1.62%	2.68%	4.02%
P/E Ratio	14.52	26.00	27.11	31.08
Price / Sales	0.57	17.40	587.92	19.77
Price / Cash	2.34	14.81	29.22	18.64
Price / Book	4.67	6.05	10.75	4.77
Net Income	$187M	$177.20M	$3.58B	$1.06B
7 Day Performance	N/A	-2.07%	-2.06%	-0.23%
1 Month Performance	0.37%	6.96%	3.32%	-0.11%
1 Year Performance	37.46%	11.42%	26.36%	16.46%

Organon & Co. Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGN Organon & Co.	2.8406 of 5 stars	$13.51 -0.1%	$11.40 -15.6%	+35.9%	$3.55B	$6.22B	14.52	10,000	Positive News
AXSM Axsome Therapeutics	3.5239 of 5 stars	$242.60 -0.7%	$258.95 +6.7%	+109.5%	$12.57B	$638.50M	N/A	380
ELAN Elanco Animal Health	3.9076 of 5 stars	$25.12 +0.5%	$28.55 +13.6%	+68.7%	$12.49B	$4.72B	N/A	9,400
RDY Dr. Reddy's Laboratories	1.7266 of 5 stars	$14.36 -0.1%	N/A	-10.8%	$12.00B	$3.58B	24.76	27,527
SMMT Summit Therapeutics	3.6734 of 5 stars	$15.93 +3.3%	$26.97 +69.3%	-38.8%	$11.97B	N/A	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:OGN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organon & Co. (OGN) Competitors

OGN vs. AXSM, ELAN, RDY, SMMT, and ARWR

How does Organon & Co. compare to Axsome Therapeutics?

Summary

How does Organon & Co. compare to Elanco Animal Health?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Summary

How does Organon & Co. compare to Summit Therapeutics?

Summary

How does Organon & Co. compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organon & Co. (OGN) Competitors

OGN vs. AXSM, ELAN, RDY, SMMT, and ARWR

How does Organon & Co. compare to Axsome Therapeutics?

Is AXSM or OGN more profitable?

Do analysts prefer AXSM or OGN?

Do institutionals & insiders hold more shares of AXSM or OGN?

Which has more volatility and risk, AXSM or OGN?

Does the media favor AXSM or OGN?

Which has higher earnings & valuation, AXSM or OGN?

Summary

How does Organon & Co. compare to Elanco Animal Health?

Do institutionals and insiders have more ownership in OGN or ELAN?

Do analysts prefer OGN or ELAN?

Is OGN or ELAN more profitable?

Which has better earnings & valuation, OGN or ELAN?

Does the media refer more to OGN or ELAN?

Which has more volatility & risk, OGN or ELAN?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Which has preferable earnings and valuation, OGN or RDY?

Does the media favor OGN or RDY?

Is OGN or RDY a better dividend stock?

Which has more risk and volatility, OGN or RDY?

Do analysts prefer OGN or RDY?

Do institutionals & insiders hold more shares of OGN or RDY?

Is OGN or RDY more profitable?

Summary

How does Organon & Co. compare to Summit Therapeutics?

Which has more risk & volatility, OGN or SMMT?

Which has stronger earnings & valuation, OGN or SMMT?

Do analysts recommend OGN or SMMT?

Is OGN or SMMT more profitable?

Does the media refer more to OGN or SMMT?

Do institutionals & insiders hold more shares of OGN or SMMT?

Summary

How does Organon & Co. compare to Arrowhead Pharmaceuticals?

Which has higher earnings & valuation, OGN or ARWR?

Which has more volatility & risk, OGN or ARWR?

Do insiders and institutionals hold more shares of OGN or ARWR?

Is OGN or ARWR more profitable?

Do analysts rate OGN or ARWR?

Does the media refer more to OGN or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools